Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Gilteritinib + OTS167|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Gilteritinib||Xospata||ASP2215||AXL Inhibitor 27 FLT3 Inhibitor 57||Xospata (gilteritinib) is a small molecule inhibitor of FLT3 and AXL that has activity against FLT3-ITD, FLT3 F691L, and FLT3 D835 mutations, potentially resulting in decreased tumor growth (J Clin Oncol 32:5s, 2014 (suppl; abstr 7070), PMID: 25891481). Xospata (gilteritinib) is FDA approved for use in patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation (ITD, D835X, and I836X) (FDA.gov).|
|OTS167||OTSSP167||OTS167 is a selective inhibitor of maternal embryonic leucine zipper kinase (MELK), which can lead to anti-tumor activity (PMID: 26918358, PMID: 30061363).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FLT3 exon 14 ins||acute myeloid leukemia||sensitive||Gilteritinib + OTS167||Preclinical - Cell line xenograft||Actionable||In a preclinical study, combination treatment with OTS167 and Xospata (gilteritinib) synergistically inhibited cell viability and led to inhibition of colony formation in acute myeloid leukuemia (AML) cell lines harboring a FLT3-ITD and patient-derived AML cell lines with a FLT3-ITD in culture, and led to improved overall survival and reduction of leukemia burden in a cell line xenograft model (PMID: 33658483).||33658483|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|